Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...

When Baso Fibonacci visited Barcelona more than 20 years ago, he marveled at how artists there didn’t sneak around when creating street art: “It opened my eyes to what could be done in the renegade ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

Abstract: The generation of electrical energy from renewable energy sources (RESs) has increased over the past few decades as part of efforts to reduce humanity's environmental impact. However, their ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

RXRX has upcoming data in H2'25 from the TUPELO trial of REC-4881 in familial adenomatous polyposis. The company will also report data from the ELUCIDATE trial of REC-617 in H2'25. A previous update ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

The command and script language of C-Kermit and Kermit 95 is described in Using C-Kermit, 2nd Edition, as supplemented by the C-Kermit 7.0 Supplement, the C-Kermit 8.0 Supplement, and the C-Kermit 9.0 ...

Hi, I have been using lsp-ai so far successfully with Ollama, but now wanted to try Gemini - since the free tier is quite generous. I am having a weird problem though, where the \n characters are ...

Recursion on Tuesday announces top-line results of the SYCAMORE trial, studying REC-994 in symptomatic CCM patients. REC-994 met its primary endpoint of safety and tolerability, but there were not yet ...